1 January 2011PatentsRichard Gough and Jane Woodhouse

For better, for worse? How shifting IP laws change the global life sciences regulatory chessboard

Is your life sciences invention—whether pharmaceutical, biologic, medical device or diagnostic—patentable? Can the term of your patent be extended? If so, what conditions apply and how long can you extend it for? Can proprietary data be used by third parties for product registration, marketing approval and market access? Can your data be used for an upcoming and competing biosimilar?

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

UK-India trade deal is ‘missed opportunity’, say industry bodies

SEPs now searchable on WIPO’s global patent database

'Nothing can stand in the way of our work': Ukraine resumes IP system

WATCH: Finding a new balance in IP protection with trade secret protection

Optis v Apple: How the court calculated the royalty rate

Apple must pay Optis $700m-the biggest patent award in UK history

Wouter Pors leaves Bird & Bird for boutique Dutch firm

US-China tariffs: What hope is there for IP rightsholders?

For better, for worse? How shifting IP laws change the global life sciences regulatory chessboard

Editor's picks

Editor's picks

More articles